ARPA-H, diversity in clinical trials bills advance through committee

Vinai Gondi, Bridget Koontz, Priya Rastogi, Lisa Lenrow named to NRG Oncology committee leadership

Vinai GondiBridget KoontzPriya RastogiLisa LenrowNRG Oncology, an NCI National Clinical Trials Network group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple committees.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Positive topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma were recently reported.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Zanzalintinib + atezolizumab improve survival in advanced CRC

Combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer live longer and control their disease better than with the standard treatment drug regorafenib, according to a study led by UCLA investigators.

October 24, 2025

Vol.51 No.39

Clinical Roundup

Trodelvy reduces risk of disease progression or death by 38% vs. chemo as first-line therapy in metastatic TNBC

Data from the phase III ASCENT-03 study demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival for Trodelvy (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors.

October 24, 2025

Vol.51 No.39

Clinical Roundup

Enhertu reduced the risk of disease recurrence or death vs. T-DM1 in high-risk HER2+ early breast cancer following neoadjuvant therapy

Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival in patients with a high risk of disease recurrence, according to results from DESTINY-Breast05 phase III trial.

October 24, 2025

Vol.51 No.39

Clinical Roundup

Enhertu + THP before surgery resulted in a pathologic complete response in high-risk HER2+ early-stage breast cancer

Positive results from the DESTINY-Breast11 phase III trial showed Enhertu (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab, and pertuzumab in the neoadjuvant setting demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response rate.

October 24, 2025

Vol.51 No.39

ARPA-H, diversity in clinical trials bills advance through committee

YOU MAY BE INTERESTED IN

Vinai Gondi, Bridget Koontz, Priya Rastogi, Lisa Lenrow named to NRG Oncology committee leadership

Ozekibart improves PFS in chondrosarcoma, registrational phase II trial shows

Zanzalintinib + atezolizumab improve survival in advanced CRC

Trodelvy reduces risk of disease progression or death by 38% vs. chemo as first-line therapy in metastatic TNBC

Enhertu reduced the risk of disease recurrence or death vs. T-DM1 in high-risk HER2+ early breast cancer following neoadjuvant therapy

Enhertu + THP before surgery resulted in a pathologic complete response in high-risk HER2+ early-stage breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login